By Kelly Cloonan
Shares of Instil Bio climbed after the company shared progress on a trial in China for its non-small cell lung cancer treatment in combination with chemotherapy and said it is preparing to start U.S. clinical development for the drug.
The stock rose 54% to $24.99 on Thursday. Shares have more than doubled over the past 12 months.
The biopharmaceutical company on Thursday said it has enrolled more than 30 patients in its Phase 2 trial in China, and over 20 have been treated with the drug combination since the end of March.
The trial is now on track to complete enrollment of about 60 patients in the third quarter and report initial results in the second half of the year, Instil said.
The drug has an objective response rate of 23%, similar to competitor bispecific antibodies at a similar stage of development, the company said.
Instil also said it plans to initiate a trial of the drug in the U.S. before the end of 2025, pending regulatory approvals. The trial will test a monotherapy dose in relapsed or refractory solid tumors, aiming to accelerate the path to a potential global Phase 3 trial of the drug in first-line non-small-cell lung cancer, the company said.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
May 22, 2025 12:45 ET (16:45 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。